首页> 外文期刊>Dermatology: international journal for clinical and investigative dermatology >Febrile ulceronecrotic mucha-habermann disease: treatment with infliximab and intravenous immunoglobulins and review of the literature.
【24h】

Febrile ulceronecrotic mucha-habermann disease: treatment with infliximab and intravenous immunoglobulins and review of the literature.

机译:高热性溃疡坏死性莫哈-哈伯曼病:英夫利昔单抗和静脉内免疫球蛋白的治疗及文献复习。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Febrile ulceronecrotic Mucha-Habermann disease (FUMHD) is a rare subtype of pityriasis lichenoides et varioliformis acuta, characterized by an acute onset of ulceronecrotic papules, rapidly coalescing into large ulcers with necrotic crusts, associated with high fever and severe systemic symptoms. We report a case of a 65-year-old woman with a resistant form of FUMHD successfully treated with a tumor necrosis factor-α (TNFα) inhibitor (infliximab). After 1 year of treatment, because of the recurrence of lesions and -occurrence of severe sepsis, we decided to change the therapeutic procedure by introducing intravenous immunoglobulin witch induced a spectacular improvement. Only few cases of FUMHD treated with intravenous immunoglobulin have been reported to date. In our case, we describe the first utilization of TNFα inhibitors in the treatment of FUMHD: TNFα inhibitors may be useful, particularly in resistant cases. Further reports are required to confirm this potential therapeutic option.
机译:发热性溃疡坏死性Mucha-Habermann病(FUMHD)是一种罕见的糠疹性糠疹性糠疹亚型,其特征是急性发作性溃疡性丘疹丘疹,迅速合并为大块溃疡并伴有坏死结皮,伴有高烧和严重的全身症状。我们报告了一例65岁女性,其抗性形式的FUMHD成功地用肿瘤坏死因子-α(TNFα)抑制剂(infliximab)治疗。经过一年的治疗,由于病变的复发和严重脓毒症的发生,我们决定通过引入静脉注射免疫球蛋白巫婆来引人注目的改善,从而改变治疗程序。迄今为止,只有少数病例接受了静脉内免疫球蛋白治疗。在我们的案例中,我们描述了TNFα抑制剂在FUMHD治疗中的首次利用:TNFα抑制剂可能有用,特别是在耐药病例中。需要进一步的报告以确认这种潜在的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号